Luis Sanchez-Perez Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery Duke University Biography Publications Institution JoVE Articles Luis Sanchez-Perez has not added a biography. If you are Luis Sanchez-Perez and would like to personalize this page please email our Author Liaison for assistance. Publications Chimeric Antigen Receptor Engineered T Cells Can Eliminate Brain Tumors and Initiate Long-term Protection Against Recurrence Oncoimmunology. 2014 | Pubmed ID: 25610729 Leveraging Chemotherapy-induced Lymphopenia to Potentiate Cancer Immunotherapy Oncoimmunology. 2014 | Pubmed ID: 25610727 EGFRvIII-specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma PloS One. 2014 | Pubmed ID: 24722266 EGFRvIII MCAR-modified T-cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity Against Tumor-antigen Loss Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2014 | Pubmed ID: 24352643 Intracerebral Delivery of a Third Generation EGFRvIII-specific Chimeric Antigen Receptor is Efficacious Against Human Glioma Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. Jan, 2014 | Pubmed ID: 24054399 Human Regulatory T Cells Kill Tumor Cells Through Granzyme-dependent Cytotoxicity Upon Retargeting with a Bispecific Antibody Cancer Immunology Research. Sep, 2013 | Pubmed ID: 24570975 Regulatory T Cells Are Redirected to Kill Glioblastoma by an EGFRvIII-targeted Bispecific Antibody Oncoimmunology. Dec, 2013 | Pubmed ID: 24475376 Rational Design and Generation of Recombinant Control Reagents for Bispecific Antibodies Through CDR Mutagenesis Journal of Immunological Methods. Sep, 2013 | Pubmed ID: 23806556 BLyS Levels Correlate with Vaccine-induced Antibody Titers in Patients with Glioblastoma Lymphodepleted by Therapeutic Temozolomide Cancer Immunology, Immunotherapy : CII. Jun, 2013 | Pubmed ID: 23591978 Myeloablative Temozolomide Enhances CD8⁺ T-cell Responses to Vaccine and is Required for Efficacy Against Brain Tumors in Mice PloS One. 2013 | Pubmed ID: 23527092 Systemic Administration of a Bispecific Antibody Targeting EGFRvIII Successfully Treats Intracerebral Glioma Proceedings of the National Academy of Sciences of the United States of America. Jan, 2013 | Pubmed ID: 23248284 Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas Current Drug Discovery Technologies. Dec, 2012 | Pubmed ID: 22339070 Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature Immunity. Dec, 2011 | Pubmed ID: 22177921 Monoclonal Antibody Blockade of IL-2 Receptor α During Lymphopenia Selectively Depletes Regulatory T Cells in Mice and Humans Blood. Sep, 2011 | Pubmed ID: 21768296 Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies Journal of Immunotherapy (Hagerstown, Md. : 1997). May, 2011 | Pubmed ID: 21499127 Tumor-specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Cancer Research. Sep, 2010 | Pubmed ID: 20647327 A Promising Approach for Treatment of Tumor-induced Bone Diseases: Utilizing Bisphosphonate Derivatives of Nucleoside Antimetabolites Bone. Jul, 2010 | Pubmed ID: 20233612 Research Highlights Immunotherapy. Nov, 2009 | Pubmed ID: 20635909 Adoptively Transferred Effector Cells Derived from Naive Rather Than Central Memory CD8+ T Cells Mediate Superior Antitumor Immunity Proceedings of the National Academy of Sciences of the United States of America. Oct, 2009 | Pubmed ID: 19805141 Antitumor Immunity Can Be Uncoupled from Autoimmunity Following Heat Shock Protein 70-mediated Inflammatory Killing of Normal Pancreas Cancer Research. Oct, 2009 | Pubmed ID: 19738045 Type 17 CD8+ T Cells Display Enhanced Antitumor Immunity Blood. Jul, 2009 | Pubmed ID: 19471017 Engagement of Toll-like Receptor-2 on Cytotoxic T-lymphocytes Occurs in Vivo and Augments Antitumor Activity FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. Oct, 2008 | Pubmed ID: 18587008 Induction of Hsp70-mediated Th17 Autoimmunity Can Be Exploited As Immunotherapy for Metastatic Prostate Cancer Cancer Research. Dec, 2007 | Pubmed ID: 18089828 Toll-like Receptors in Tumor Immunotherapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2007 | Pubmed ID: 17875756 Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T-cell Therapy Cancer Research. Jan, 2007 | Pubmed ID: 17210711 Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas Journal of Immunology (Baltimore, Md. : 1950). Sep, 2006 | Pubmed ID: 16951382 Tumor-targeted, Systemic Delivery of Therapeutic Viral Vectors Using Hitchhiking on Antigen-specific T Cells Nature Medicine. Oct, 2005 | Pubmed ID: 16170322 Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy Journal of Immunology (Baltimore, Md. : 1950). May, 2005 | Pubmed ID: 15843579 Potent Selection of Antigen Loss Variants of B16 Melanoma Following Inflammatory Killing of Melanocytes in Vivo Cancer Research. Mar, 2005 | Pubmed ID: 15753401 A Simple Method to Cure Established Tumors by Inflammatory Killing of Normal Cells Nature Biotechnology. Sep, 2004 | Pubmed ID: 15300260 Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care Katherine Riccione1,2, Carter M. Suryadevara1,3, David Snyder1, Xiuyu Cui1, John H. Sampson1,2,3, Luis Sanchez-Perez1 1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University, 2Department of Biomedical Engineering, Duke University, 3Department of Pathology, Duke University JoVE 52397 Imunologia e Infecção
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care Katherine Riccione1,2, Carter M. Suryadevara1,3, David Snyder1, Xiuyu Cui1, John H. Sampson1,2,3, Luis Sanchez-Perez1 1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University, 2Department of Biomedical Engineering, Duke University, 3Department of Pathology, Duke University JoVE 52397 Imunologia e Infecção